Aims Sacubitril‐valsartan has been shown to have superior effects over angiotensin‐
converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure …

This review aims to assess the benefits and adverse effects of sacubitril/valsartan in heart
failure, with a focus on important patient outcomes. A systematic review was conducted of …

Background Sacubitril‐valsartan, an inhibitor of the angiotensin receptor neprilysin (ARNi),
has been purported to exhibit superiority over angiotensin converting enzyme (ACE) …

One of the defining features of heart failure (HF) is neurohormonal activation. The renin-
angiotensin-aldosterone-system (RAAS) and sympathetic nervous system (SNS) cause …

Background Angiotensin receptor and neprilysin inhibition (ARNI) has been shown to
reduce cardiovascular mortality by 20% as compared with enalapril in a randomized …

Current guidelines recommend angiotensin receptor blocker neprilysin inhibitors
(ARNI)(sacubitril/valsartan) as a replacement for angiotensin-converting-enzymeinhibitor …

Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at
high risk for HF progression and death. Sacubitril/valsartan (previously known as LCZ696) is …

Real-life data confirming the favourable renal outcome in patients with heart failure (HF)
treated with Sacubitril/Valsartan, previously found in several trials (RCTs), are still scant. We …

Current international guidelines recommend switching angiotensin converting enzyme
inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) to sacubitril/valsartan (S/V) in …

Background: To investigate the efficacy and safety of sacubitril-valsartan in patients with
heart failure, relevant randomized clinical trials (RCTs) were analyzed. Methods: We used …